Morphological variations of papillary muscles in the mitral valve complex in human cadaveric hearts

Share this Article

Singapore Med J 2013; 54:44-48; http://dx.doi.org/10.11622/smedj.2013011
Morphological variations of papillary muscles in the mitral valve complex in human cadaveric hearts

Gunnal SA, Wabale RN, Farooqui MS
Correspondence: Sandhya Arvind Gunnal, sandhyagunnal@yahoo.com

ABSTRACT
Introduction Papillary muscle rupture and dysfunction can lead to complications of prolapsed mitral valve and mitral regurgitation. Multiple operative procedures of the papillary muscles, such as resection, repositioning and realignment, are carried out to restore normal physiological function. Therefore, it is important to know both the variations and the normal anatomy of papillary muscles.

Methods This study was carried out on 116 human cadaveric hearts. The left ventricles were opened along the left border in order to view the papillary muscles. The number, shape, position and pattern of the papillary muscles were observed.
Results In this series, the papillary muscles were mostly found in groups instead of in twos, as is described in standard textbooks. Four different shapes of papillary muscles were identified – conical, broad-apexed, pyramidal and fan-shaped. We also discovered various patterns of papillary muscles.
Conclusion No two mitral valve complexes have the same architectural arrangement. Each case seems to be unique. Therefore, it is important for scientists worldwide to study the variations in the mitral valve complex in order to ascertain the reason behind each specific architectural arrangement. This will enable cardiothoracic surgeons to tailor the surgical procedures according to the individual papillary muscle pattern.
Keywords: chordae tendineae, heart, left ventricle, mitral valve complex, papillary muscles
Singapore Med J 2013; 54:44-48

REFERENCES

1. Skwarek M, Hreczecha J, Grzybiak M, Kosi?ski A. Remarks on the morphology of the papillary muscles of the right ventricle. Folia Morphol (Warsz) 2005; 64:176-82.
 
2. Grochowski P. [Kszta?towanie si? mi??nia brodawkowatego tylnego w prawej komorze serca w rozwoju osobniczym cz?owieka] (dissertation). Gda?sk: Medical University of Gdansk, 2001. Russian.
 
3. Victor S, Nayak VM. Variations in the papillary muscles of the normal mitral valve and their surgical relevance. J Card Surg 1995; 10:597-607.
http://dx.doi.org/10.1111/j.1540-8191.1995.tb00642.x
 
4. Standring S. Gray's Anatomy. 39th ed. Edinburgh: Elsevier Churchill Livingstone 2005, 1006-8.
 
5. Ho SY. Anatomy of the mitral valve. Heart 2002; 88 suppl 4:iv5-iv10.
http://dx.doi.org/10.1136/heart.88.suppl_4.iv5
PMid:12369589 PMCid:1876279
 
6. Oosthoek PW, Wenink AC, Wisse LJ, Gittenberger-de Groot AC. Development of the papillary muscles of the mitral valve: morphogenetic background of parachute-like asymmetric mitral valves and other mitral valve anomalies. J Thorac Cardiovasc Surg 1998; 116:36-46.
http://dx.doi.org/10.1016/S0022-5223(98)70240-5
 
7. Madu EC, D'Cruz IA. The vital role of papillary muscles in mitral and ventricular function: echocardiographic insights. Clin Cardiol 1997; 20:93-8.
http://dx.doi.org/10.1002/clc.4960200203
 
8. Bryant R 3rd, Smedira NG. Papillary muscle realignment for symptomatic left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg 2008; 135:223-4.
http://dx.doi.org/10.1016/j.jtcvs.2007.08.034
PMid:18179954
 
9. Yousefnia MA, Mandegar MH, Roshanali F, Alaeddini F, Amouzadeh F. Papillary muscle repositioning in mitral valve replacement in patients with left ventricular dysfunction. Ann Thorac Surg 2007; 83:958-63.
http://dx.doi.org/10.1016/j.athoracsur.2006.08.045
 
10.Maron BJ, Nishimura RA, Danielson GK. Pitfalls in clinical recognition and a novel operative approach for hypertrophic cardiomyopathy with severe outflow obstruction due to anomalous papillary muscle. Circulation 1998; 98:2505-8.
http://dx.doi.org/10.1161/01.CIR.98.23.2505
 
11. Ranganathan N, Burch GE. Gross morphology and arterial supply of the papillary muscles of the left ventricle of man. Am Heart J 1969; 77:506-16.
http://dx.doi.org/10.1016/0002-8703(69)90160-4
 
12.Roberts WC, Cohen LS. Left ventricular papillary muscles. Description of the normal and a survey of conditions causing them. Circulation 1972; 46:138-54.
http://dx.doi.org/10.1161/01.CIR.46.1.138
 
 
13.Dreyfus GD, Souza Neto O, Aubert S. Papillary muscle repositioning for repair of anterior leaflet prolapse caused by chordal elongation. J Thorac Cardiovasc Surg 2006; 132:578-84.
http://dx.doi.org/10.1016/j.jtcvs.2006.06.003
 
 
14. Fumimoto K, Fukui T, Shimokawa T, Takanashi S. Papillary muscle realignment and mitral annuloplasty in patients with severe ischemic mitral regurgitation and dilated heart. Interact Cardiovasc Thorac Surg 2008; 7:368-71.
http://dx.doi.org/10.1510/icvts.2008.175125
 
15. Kochi K, Okada K, Watari M, Orihashi K, Sueda T. Papillary muscle resection as a treatment for midventricular obstruction. Ann Thorac Cardiovasc Surg 2002; 8:109-11.

Demographics of severe valvular aortic stenosis in Singapore

Share this Article

Singapore Med J 2013; 54:36-39; http://dx.doi.org/10.11622/smedj.2013009
Demographics of severe valvular aortic stenosis in Singapore

Tay EL, Lew PS, Poh KK, Saclolo R, Chia BL, Yeo TC, Tan HC, Yip JW
Correspondence: Dr Edgar Tay, Edgar_Tay@nuhs.edu.sg

ABSTRACT
Introduction The treatment of aortic valve stenosis (AS) is seeing renewed interest mainly due to the availability of transcatheter therapies. However, the number of epidemiological studies of this disease in Singapore is limited. We aimed to describe the aetiology and clinical presentation of AS in Singapore, as well as patients’ attitudes toward it. Our findings may facilitate the future planning and utilisation of resources to better manage these patients.

Methods 249 consecutive patients who underwent transthoracic echocardiography (from April 1999 to April 2008) and diagnosed with severe AS were assessed. Demographic and clinical data were collected, and patients’ decisions on surgery were determined.
Results The mean patient age was 71 (range 23–98) years. 50.2% of patients were male. The commonest presenting symptom was dyspnoea, and 40 (16.0%) patients had coexistent atrial fibrillation. The aetiology of AS was degenerative in 216 (86.7%), rheumatic in 11 (4.4%) and related to a bicuspid valve in 22 (8.9%) patients. The average peak velocity across the aortic valve was 4.2 ± 0.8 m/s and the mean aortic valve area was 0.76 ± 0.13 cm2. The overall mean logistic
EuroSCORE was 10.7 ± 12.3. 105 (42.2%) patients who were offered surgery refused. 87 (35%) deaths were seen during the follow-up period (mean duration 14.5 months), which also saw 68 (27%) patients undergo surgery and 86 (34%) patients hospitalised for heart failure.
Conclusion Degenerative AS was the commonest aetiology in this contemporary cohort of patients. Despite the known benefits of surgery, the refusal rate for surgery remained high.
Keywords: epidemiology, severe aortic stenosis, transcatheter aortic valve implantation
Singapore Med J 2013; 54:36-39; http://dx.doi.org/10.11622/smedj.2013009
REFERENCES
1. Tseng EE, Lee CA, Cameron DE, et al. Aortic valve replacement in the elderly. Risk factors and long-term results. Ann Surg 1997; 225:793-802. 
http://dx.doi.org/10.1097/00000658-199706000-00017
 
2. Antunes MJ. Aortic stenosis in the elderly: Rethinking strategies. Eur J Cardiothorac Surg 2006; 30:713-5. 
http://dx.doi.org/10.1016/j.ejcts.2006.08.006
 
3. Bouma BJ, van Den Brink RB, van Der Meulen JH, et al. To operate or not on elderly patients with aortic stenosis: the decision and its consequences. Heart 1999; 82:143-8.
 
4. Descoutures F, Himbert D, Lepage L, et al. Contemporary surgical or percutaneous management of severe aortic stenosis in the elderly. Eur Heart J 2008; 29:1410-7.
http://dx.doi.org/10.1093/eurheartj/ehn081
 
5. Iung B. Management of the elderly patient with aortic stenosis. Heart 2008; 94:519-24. 
http://dx.doi.org/10.1136/hrt.2007.122804
 
6. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Survival in elderly patients with severe aortic stenosis is dramatically improved by aortic valve replacement: Results from a cohort of 277 patients aged > or =80 years. Eur J Cardiothorac Surg 2006; 30:722-7. 
http://dx.doi.org/10.1016/j.ejcts.2006.07.028
 
7. Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high-risk patients using the second-and current third-generation self-expanding CoreValve prosthesis: device success and 30-day clinical outcome. J Am Coll Cardiol 2007; 50:69-76. 
http://dx.doi.org/10.1016/j.jacc.2007.04.047
 
8. Leon MB, Smith CR, Mack M, et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 2010; 363:1597-607. 
http://dx.doi.org/10.1056/NEJMoa1008232
 
9. Bleiziffer S, Ruge H, Mazzitelli D, et al. Results of percutaneous and transapical transcatheter aortic valve implantation performed by a surgical team. Eur J Cardiothorac Surg 2009; 35:615-20.
http://dx.doi.org/10.1016/j.ejcts.2008.12.041
 
10. Bach DS, Siao D, Girard SE, et al. Evaluation of patients with severe symptomatic aortic stenosis who do not undergo aortic valve replacement: the potential role of subjectively overestimated operative risk. Circ Cardiovasc Qual Outcomes 2009; 2:533-9. 
http://dx.doi.org/10.1161/CIRCOUTCOMES.109.848259
 
11. Iung B, Cachier A, Baron G, et al. Decision-making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J 2005; 26:2714-20. 
http://dx.doi.org/10.1093/eurheartj/ehi471
 
12. Rumsfeld JS. Valve surgery in the elderly: question of quality (of life)? J Am Coll Cardiol 2003; 42:1215-7. 
http://dx.doi.org/10.1016/S0735-1097(03)00950-1
 
13. Baumgartner H, Hung J, Bermejo J, et al. Echocardiographic assessment of valve stenosis: EAE/ASE recommendations for clinical practice. J Am Soc Echocardiogr 2009; 22:1-23. 
http://dx.doi.org/10.1016/j.echo.2008.11.029
 
14. Nashef SA, Roques F, Michel P, et al. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg 1999; 16:9-13. 
http://dx.doi.org/10.1016/S1010-7940(99)00134-7
 
15. Zingone B, Pappalardo A, Dreas L. Logistic versus additive EuroSCORE. A comparative assessment of the two models in an independent population sample. Eur J Cardiothorac Surg 2004; 26:1134-40. 
http://dx.doi.org/10.1016/j.ejcts.2004.09.003
 
16. Piazza N, Wenaweser P, van Gameren M, et al. Relationship between the logistic EuroSCORE and the Society of Thoracic Surgeons Predicted Risk of Mortality score in patients implanted with the CoreValve ReValving system--a Bern-Rotterdam Study. Am Heart J 2010; 159:323-9. 
http://dx.doi.org/10.1016/j.ahj.2009.11.026
 
17. Rosenhek R, Zilberszac R, Schemper M, et al. Natural history of very severe aortic stenosis. Circulation 2010; 121:151-6. 
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.894170
 
18. Varadarajan P, Kapoor N, Bansal RC, Pai RG. Clinical profile and natural history of 453 nonsurgically managed patients with severe aortic stenosis. Ann Thorac Surg 2006; 82:2111-5. 
http://dx.doi.org/10.1016/j.athoracsur.2006.07.048
 
19. Wijesinghe N, Ye J, Rodés-Cabau J, et al. Transcatheter aortic valve implantation in patients with bicuspid aortic valve stenosis. JACC Cardiovasc Interv 2010; 3:1122-5.6
http://dx.doi.org/10.1016/j.jcin.2010.08.016
 
20. Webb JG, Chandavimol M, Thompson CR, et al. Percutaneous aortic valve implantation retrograde from the femoral artery. Circulation 2006; 113:842-50. 
http://dx.doi.org/10.1161/CIRCULATIONAHA.105.582882

Public perceptions, knowledge and awareness of cholesterol management in Singapore: a prospective pilot study

Share this Article

Singapore Med J 2013; 54:32-35; http://dx.doi.org/10.11622/smedj.2013008
Public perceptions, knowledge and awareness of cholesterol management in Singapore: a prospective pilot study

Aung TH, Go YY, Low LP, Chua T
Correspondence: A/Prof Terrance Siang Jin Chua, terrance.chua.s.j@nhcs.com.sg

ABSTRACT
Introduction Hyperlipidaemia is a major risk factor for coronary artery disease (CAD). Its effective treatment has been shown to reduce the incidence of cardiovascular events, both in secondary and primary prevention. An essential component of risk factor management at the community level is public awareness and knowledge of treatment benefits. However, this data is limited in Singapore.
Methods A cross-sectional survey questionnaire of public perception and knowledge on cholesterol treatment among adult Singaporeans aged 30–69 years was commissioned by the Singapore Heart Foundation and conducted by a professional market survey company. Regional quota sampling was performed to ensure that the sample was representative of the Singapore population. This was followed by random sampling of households and respondents.
Results Of the 365 respondents, 40.9% were male, 70.3% were Chinese, 18.8% Malay and 10.9% Indian. The mean age was 47.5 years. Although 81.9% of respondents had medical check-ups involving blood tests, only 11.0% knew their actual cholesterol levels. A third of the respondents saw herbal medicine as healthier and safer than Western medication. More than 80% of respondents believed that diet and exercise were equally effective at lowering cholesterol as medication. About half of the respondents associated long-term use of statins with damage to the liver and kidney, while a third associated chronic statin use with the development of cancer.
Conclusion There are gaps in the level of public awareness and understanding of cholesterol treatment in Singapore. Common misconceptions should be addressed, as they could potentially impair effective management or treatment compliance.

Keywords: cholesterol, health knowledge, health surveys, hyperlipidaemia
Singapore Med J 2013; 54:32-35; http://dx.doi.org/10.11622/smedj.2013008

REFERENCES

1. Ministry of Health, Singapore. Singapore Health Facts 2010. Singapore, 2010.
 
2. Ministry of Health, Singapore. Disease Burden. In: Singapore Health Facts [online]. Available at: www.moh.gov.sg/content/moh_web/home/statistics/Health_Facts_Singapore/Di.... Accessed August 15, 2012.
 
3. Cleeman JI, Lenfant C. The National Cholesterol Education Program: progress and prospects. JAMA 1998; 280:2099-104. 
http://dx.doi.org/10.1001/jama.280.24.2099
 
4. Ford I, Murray H, Packard CJ, et al. West of Scotland Coronary Prevention Study Group. Long-term follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-86. 
http://dx.doi.org/10.1056/NEJMoa065994
 
5. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279:1615-22. 
http://dx.doi.org/10.1001/jama.279.20.1615
 
6. Heart Protection Study Collaborative Group, Bulbulia R, Bowman L, Wallendszus K, et al. Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 highrisk individuals: a randomised controlled trial. Lancet 2011; 378:2013-20. http://dx.doi.org/10.1016/S0140-6736(11)61125-2
 
7. Nash IS, Mosca L, Blumenthal RS, et al. Contemporary awareness and understanding of cholesterol as a risk factor: results of an American Heart Association national survey. Arch Intern Med 2003; 163:1597-600.
http://dx.doi.org/10.1001/archinte.163.13.1597
 
8. Goldman RE, Parker DR, Eaton CB, et al. Patients' perceptions of cholesterol, cardiovascular disease risk, and risk communication strategies. Ann Fam Med 2006; 4:205-12.
http://dx.doi.org/10.1370/afm.534
 
9. Yoon SS, Carroll MD, Johnson CL, Gu Q. Cholesterol management in the United States: the national health and nutrition examination survey, 1999 to 2006. Ann Epidemiol 2011; 21:318-26.
http://dx.doi.org/10.1016/j.annepidem.2011.01.004
 
10. Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97:52C-60C. 
http://dx.doi.org/10.1016/j.amjcard.2005.12.010
 
11. Guyton JR. Benefit versus risk in statin treatment. Am J Cardiol 2006; 97:95C-97C. 
http://dx.doi.org/10.1016/j.amjcard.2005.12.016
 
12. Kandula NR, Tirodkar MA, Lauderdale DS, et al. Knowledge gaps and misconceptions about coronary heart disease among US South Asians. Am J Prev Med 2010; 38:439-42. 
http://dx.doi.org/10.1016/j.amepre.2009.12.034

Peripartum cardiomyopathy: experience in an Asian tertiary centre

Share this Article

Singapore Med J 2013; 54:24-27; http://dx.doi.org/10.11622/smedj.2013006
Peripartum cardiomyopathy: experience in an Asian tertiary centre

Lim CP, Sim KL
Correspondence: Dr Choon Pin Lim, lim.choon.pin@nhcs.com.sg

ABSTRACT
Introduction Peripartum cardiomyopathy (PPCM) is a rare but life-threatening condition. We report 11 patients admitted to the National Heart Centre Singapore with a diagnosis of PPCM over a period of 14 months.
Methods Baseline demographics, pregnancy history, haematology, serum biochemistry and echocardiographic findings of women admitted with a diagnosis of PPCM were analysed.
Results The incidence of PPCM was 0.89 per 1,000 live births in our cohort. 63.6% of the patients were Malay and 27.3% were Chinese. 45.5% of the patients were smokers and 45.5% had a history of pregnancy-induced hypertension or preeclampsia. There was no maternal mortality. Mean left ventricular ejection fractions at diagnosis and at six months were 26.9% ± 9.1% and 51.9% ± 10.6%, respectively. Mean left ventricular internal diameters in end-diastole at diagnosis and at six months were 5.5 ± 0.5 cm and 5.1 ± 0.6 cm, respectively. All patients were treated successfully for the acute episode and all but one patient had returned to New York Heart Association functional class I status at six months.
Conclusion PPCM remains a rare condition and appears to occur more commonly in Malay patients. Smoking and pregnancy-induced hypertension appear to be significant risk factors. While short-term outcome remains excellent, collaborative studies with other tertiary centres will help enhance our understanding of the long-term management of and clinical outcomes in these patients.

Keywords:cardiomyopathy, heart failure, peripartum, pregnancy
Singapore Med J 2013; 54:24-27; http://dx.doi.org/10.11622/smedj.2013006

REFERENCES
1. O'Connell JB, Costanzo-Nordin MR, Subramanian R, et al. Peripartum cardiomyopathy: clinical, hemodynamic, histologic and prognostic characteristics. J Am Coll Cardiol 1986; 8:52-6.
http://dx.doi.org/10.1016/S0735-1097(86)80091-2
 
2. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J 2000; 140:785- 91.
http://dx.doi.org/10.1067/mhj.2000.110091
 
3. Midei MG, DeMent SH, Feldman AM, Hutchins GM, Baughman KL. Peripartum myocarditis and cardiomyopathy. Circulation 1990; 81:922-8. 
http://dx.doi.org/10.1161/01.CIR.81.3.922
 
4. Pearson G, Veille J, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung and Blood Institute and office of rare diseases (National Institute of Health) workshop recommendations and review. JAMA 2000; 283:1183-8. 
http://dx.doi.org/10.1001/jama.283.9.1183
 
5. Sliwa K, Fett J, Elkayam U. Peripartum cardiomyopathy. Lancet 2006; 368:687-93. 
http://dx.doi.org/10.1016/S0140-6736(06)69253-2
 
6. Mayosi BM. Contemporary trends in the epidemiology and management of cardiomyopathy and pericarditis in sub-Saharan Africa. Heart 2007; 93:1176-83. 
http://dx.doi.org/10.1136/hrt.2007.127746
 
7. Brar SS, Khan SS, Sandhu GK, et al. Incidence, mortality, and racial differences in peripartum cardiomyopathy. Am J Cardiol 2007; 100:302-4. 
http://dx.doi.org/10.1016/j.amjcard.2007.02.092
 
8. Lok SI, Kirkels JH, Klöpping C, Doevendans PA, de Jonge N. Peripartum cardiomyopathy: the need for a national database. Neth Heart J 2011; 19:126-33. 
http://dx.doi.org/10.1007/s12471-011-0083-7
 
9. Demakis JG, Rahimtoola SH. Peripartum cardiomyopathy. Circulation 1971; 44:964-8.
http://dx.doi.org/10.1161/01.CIR.44.5.964
 
10. Selle T, Renger I, Labidi S, Bultmann I, Hilfiker-Kleiner D. Reviewing peripartum cardiomyopathy: current state of knowledge. Future Cardiol 2009; 5:175-89. 
http://dx.doi.org/10.2217/14796678.5.2.175
 
11. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Clin Proc 2005; 80:1602-6.
http://dx.doi.org/10.4065/80.12.1602
 
12. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, et al. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. -Results from the Japanese Nationwide survey of peripartum cardiomyopathy. Circ J 2011; 75:1975-81.
http://dx.doi.org/10.1253/circj.CJ-10-1214
 
13. Gevaert S, Van Belleghem Y, Bouchez S, et al. Acute and critically ill peripartum cardiomyopathy and 'bridge to' therapeutic options: a single center experience with intra-aortic balloon pump, extracorporeal membrane oxygenation and continuous-flow left ventricular assist devices. Crit Care 2011; 15:R93. 
http://dx.doi.org/10.1186/cc10098
 
14. Biteker M, Duran NE, Kaya H, et al. Effect of levosimendan and predictors of recovery in patients with peripartum cardiomyopathy, a randomized clinical trial. Clin Res Cardiol 2011; 100:571-7. 
http://dx.doi.org/10.1007/s00392-010-0279-7
 
15. Hilfiker-Kleiner D, Kaminski K, Podewski E, et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007; 128:589-600. 
http://dx.doi.org/10.1016/j.cell.2006.12.036
 
16. Sliwa K, Blauwet L, Tibazarwa K, et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy. A proof-of-concept pilot study. Circulation 2010; 121:1465-73. 
http://dx.doi.org/10.1161/CIRCULATIONAHA.109.901496
 
17. Amos AM, Jaber W, Russell SD. Improved outcome in peripartum cardiomyopathy with contemporary. Am Heart J 2006; 152:509-13. 
http://dx.doi.org/10.1016/j.ahj.2006.02.008
 
18. Goland S, Bitar F, Modi K, et al. Evaluation of the clinical relevance of baseline left ventricular ejection fraction as a predictor of recovery or persistence of severe dysfunction in women in the United States with peripartum cardiomyopathy. J Card Fail 2011; 17:426-30. 
http://dx.doi.org/10.1016/j.cardfail.2011.01.007

A prospective comparison of chronic primary angle-closure glaucoma versus primary open-angle glaucoma in Singapore

Share this Article

Singapore Med J 2013; 54(3): 140-145; http://dx.doi.org/doi:10.11622/smedj.2013049
A prospective comparison of chronic primary angle-closure glaucoma versus primary open-angle glaucoma in Singapore

Ngo CS, Aquino MC, Noor S, Loon SC, Sng CC, Gazzard G, Wong WL, Chew PT
Correspondence: Dr Cheryl SF Ngo, cherylngo@gmail.com

ABSTRACT
Introduction To describe the optic disc, visual field and ocular characteristics of a consecutive cohort of Asian patients with chronic primary angle-closure glaucoma (CPACG), and compare them with those having primary open-angle glaucoma (POAG).
Methods In a prospective comparative case series of new patients with POAG or CPACG in Singapore, all patients underwent visual acuity assessment, slit-lamp examination, tonometry, gonioscopy, refraction, Heidelberg Retina Tomograph (HRT) and Humphrey visual field (HVF) assessment.
Results 98 patients were enrolled (POAG n = 48; CPACG n = 50). CPACG patients were significantly older (66.5 ± 9.2 years vs. 64.1 ± 13.5 years; p = 0.027) and mostly female (p = 0.004). CPACG eyes had significantly higher intraocular pressure (26.9 ± 6.9 mmHg vs. 24.5 ± 3.3 mmHg; p = 0.03), shorter axial length (22.89 ± 0.97 mm vs. 24.26 ± 1.79 mm; p < 0.001) and shallower anterior chamber depth (2.60 ± 0.25 mm vs. 3.16 ± 0.48 mm; p < 0.001). HVF mean deviation or pattern standard deviation (PSD) did not differ significantly between POAG and CPACG eyes, but the latter had a lower PSD for a given mean deviation. HRT parameters between the two groups were not significantly different.
Conclusion In this study, CPACG eyes had significantly higher presenting intraocular pressure than POAG eyes, but there were no significant differences in optic disc topography. A majority of the patients in both groups had moderate field defects at the time of presentation, followed by severe and then mild defects. The field loss in CPACG eyes was more diffuse than that in POAG eyes.

Keywords: field of vision, intraocular pressure, optic nerve
Singapore Med J 2013; 54(3): 140-145; doi:10.11622/smedj.2013049

REFERENCES

1. Foster PJ, Oen FT, Machin D, et al. The prevalence of glaucoma in Chinese residents of Singapore: a cross-sectional population survey of the Tanjong Pagar district. Arch Ophthalmol 2000; 118:1105-11.
http://dx.doi.org/10.1001/archopht.118.8.1105
 
2. Tielsch JM, Sommer A, Katz J, et al. Racial variations in the prevalence of primary open-angle glaucoma. The Baltimore Eye Survey. JAMA 1991; 17:369-74.
http://dx.doi.org/10.1001/jama.1991.03470030069026
 
3. Foster PJ. The epidemiology of primary angle closure and associated glaucomatous optic neuropathy. Semin Ophthalmol 2002; 17:50-8.
http://dx.doi.org/10.1076/soph.17.2.50.14718
 
4. Aung T, Lim MC, Chan YH, Rojanapongpun P, Chew PT. Configuration of the drainage angle, intraocular pressure, and optic disc cupping in subjects with chronic angle-closure glaucoma. Ophthalmology 2005; 112:28-32.
http://dx.doi.org/10.1016/j.ophtha.2004.06.033
 
5. Foulds WS, Phillips CI. Some observations on chronic closed-angle glaucoma. Br J Ophthalmol 1957; 41:208-13.
http://dx.doi.org/10.1136/bjo.41.4.208
 
6. Lau LI, Liu CJ, Chou JC, Hsu WM, Liu JH. Patterns of visual field defects in chronic angle-closure glaucoma with different disease severity. Ophthalmology 2003; 110:1890-4.
http://dx.doi.org/10.1016/S0161-6420(03)00666-3
 
7. Goldberg I. Optic disc and visual field changes in primary open angle glaucoma. Aust J Ophthalmol 1981; 9:223-9.
http://dx.doi.org/10.1111/j.1442-9071.1981.tb01017.x
 
8. Bartz-Schmidt KU, Thumann G, Jonescu-Cuypers CP, Krieglstein GK. Quantitative morphologic and functional evaluation of the optic nerve head in chronic open-angle glaucoma. Surv Ophthalmol 1999; 44 suppl 1:S41-53.
http://dx.doi.org/10.1016/S0039-6257(99)00076-4
 
9. Macri A, Rolando M, Corallo G, et al. A comparative study of computerised visual field testing and optic disc morphometric parameters in the follow-up of primary open angle glaucoma. Eye (Lond) 1998; 12:916-20.
http://dx.doi.org/10.1038/eye.1998.238
 
10. Gazzard G, Foster PJ, Viswanathan AC, et al. The severity and spatial distribution of visual field defects in primary glaucoma: a comparison of primary open-angle glaucoma and primary angle-closure glaucoma. Arch Ophthalmol 2002; 120:1636-43.
http://dx.doi.org/10.1001/archopht.120.12.1636
 
11. Foster PJ, Aung T, Nolan WP, et al. Defining "occludable" angles in population surveys: drainage angle width, peripheral anterior synechiae, and glaucomatous optic neuropathy in east Asian people. Br J Ophthalmol 2004; 88:486-90.
http://dx.doi.org/10.1136/bjo.2003.020016
 
12. Saw SM, Gazzard G, Au Eong KG, Oen F, Seah S. Utility values in Singapore Chinese adults with primary open-angle and primary angle-closure glaucoma. J Glaucoma 2005; 14:455-62.
http://dx.doi.org/10.1097/01.ijg.0000185434.08051.82
 
13. Scheie H. Width and pigmentation of the angle of the anterior chamber; a system of grading by gonioscopy. AMA Arch Ophthalmol 1957; 58:510-12.
http://dx.doi.org/10.1001/archopht.1957.00940010526005
 
14. Bowd C, Zangwill LM, Blumenthal EZ, et al. Imaging of the optic disc and retinal nerve fiber layer: the effects of age, optic disc area, refractive error, and gender. J Opt Soc Am A Opt Image Sci Vis 2002; 19:197-207.
http://dx.doi.org/10.1364/JOSAA.19.000197
 
15. Advanced Glaucoma Intervention Study. 2. Visual field test scoring and reliability. Ophthalmology 1994; 101:1445-55.
PMid:7741836
 
16. Sihota R. An Indian perspective on primary angle closure and glaucoma. Indian J Ophthalmol 2011; 59 Suppl:S76-81.
http://dx.doi.org/10.4103/0301-4738.73687
 
17. Boland MV, Zhang L, Broman AT, Jampel HD, Quigley HA. Comparison of optic nerve head topography and visual field in eyes with open-angle and angle-closure glaucoma. Ophthalmology 2008; 115:239-45.
http://dx.doi.org/10.1016/j.ophtha.2007.03.086
 
18. Thomas R, Muliyil J, Simha RA, Parikh RS. Heidelberg Retinal Tomograph (HRT 2) parameters in primary open angle glaucoma and primary angle closure glaucoma: a comparative study in an Indian population. Ophthalmic Epidemiol 2006; 13:343-50.
http://dx.doi.org/10.1080/09286580600850983
 
19. Shabana N, Aquino MC, See J, et al. Quantitative evaluation of anterior chamber parameters using anterior segment optical coherence tomography in primary angle closure mechanisms. Clin Experiment Ophthalmol 2012; 40:792-80.
http://dx.doi.org/10.1111/j.1442-9071.2012.02805.x
 
20. Friedman DS, Foster PJ, Aung T, He M. Angle closure and angle-closure glaucoma: what we are doing now and what we will be doing in the future. Clin Experiment Ophthalmol 2012; 40:381-7.
http://dx.doi.org/10.1111/j.1442-9071.2012.02774.x
 
21. Amerasinghe N, Aung T. Angle-closure: risk factors, diagnosis and treatment. Prog Brain Res 2008; 173:31-45.
http://dx.doi.org/10.1016/S0079-6123(08)01104-7
 
22. Wang N, Wu H, Fan Z. Primary angle closure glaucoma in Chinese and Western populations. Chin Med J (Engl) 2002; 115:1706-15.
 
23. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 2000; 44:367-408.
http://dx.doi.org/10.1016/S0039-6257(00)00110-7
 
24. Broman AT, Congdon NG, Bandeen-Roche K, Quigley HA. Influence of corneal structure, corneal responsiveness, and other ocular parameters on tonometric measurement of intraocular pressure. J Glaucoma 2007; 16:581-8.
http://dx.doi.org/10.1097/IJG.0b013e3180640f40
 
25. Ehlers N. On corneal thickness and intraocular pressure. II. A clinical study on the thickness of the corneal stroma in glaucomatous eyes. Acta Ophthalmol (Copenh) 1970; 48:1107-12.
http://dx.doi.org/10.1111/j.1755-3768.1970.tb06591.x
 
26. Iester M, Mete M, Figus M, Frezzotti P. Incorporating corneal pachymetry into the management of glaucoma. J Cataract Refract Surg 2009; 35:1623-8.
http://dx.doi.org/10.1016/j.jcrs.2009.05.015
 
27. Goldmann H, Schmidt T. [Applanation tonometry]. Ophthalmologica 1957; 134:221-42. German.
http://dx.doi.org/10.1159/000303213
 
28. Wong TT, Wong TY, Foster PJ, et al. The relationship of intraocular pressure with age, systolic blood pressure, and central corneal thickness in an asian population. Invest Ophthalmol Vis Sci 2009; 50:4097-102.
http://dx.doi.org/10.1167/iovs.08-2822
 
29. Casson RJ, Baker M, Edussuriya K, et al. Prevalence and determinants of angle closure in central Sri Lanka: the Kandy Eye Study. Ophthalmology 2009; 116:1444-9.
http://dx.doi.org/10.1016/j.ophtha.2009.03.005
 
30. Vijaya L, George R, Arvind H, et al. Prevalence of primary angle-closure disease in an urban south Indian population and comparison with a rural population. The Chennai Glaucoma Study. Ophthalmology 2008; 115:655-60.
http://dx.doi.org/10.1016/j.ophtha.2007.05.034
 
31. Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthalmol 2003; 48 suppl 1:S3-7.
http://dx.doi.org/10.1016/S0039-6257(03)00006-7
 
32. Morrison JC, Johnson EC, Cepurna W, Jia L. Understanding mechanisms of pressure-induced optic nerve damage. Prog Retin Eye Res 2005; 24:217-40.
http://dx.doi.org/10.1016/j.preteyeres.2004.08.003
 
33. Agarwal HC, Gulati V, Sihota R. The normal optic nerve head on Heidelberg Retina Tomograph II. Indian J Ophthalmol 2003; 51:25-33.
PMid:12701859
 
34. Jonas JB, Fernández MC, Naumann GO. Correlation of the optic disc size to glaucoma susceptibility. Ophthalmology 1991; 98:675-80.
PMid:2062501
 
35. Oliveira C, Harizman N, Girkin CA, et al. Axial length and optic disc size in normal eyes. Br J Ophthalmol 2007; 91:37-9.
http://dx.doi.org/10.1136/bjo.2006.102061
 
36. Sihota R, Sony P, Gupta V, Dada T, Singh R. Comparing glaucomatous optic neuropathy in primary open angle and chronic primary angle closure glaucoma eyes by optical coherence tomography. Ophthalmic Physiol Opt 2005; 25:408-15.
http://dx.doi.org/10.1111/j.1475-1313.2005.00304.x
 
37. Bonomi L, Marraffa M, Marchini G, Canali N. Perimetric defects after a single acute angle-closure glaucoma attack. Graefes Arch Clin Exp Ophthalmol 1999; 237:908-14.
http://dx.doi.org/10.1007/s004170050385
 
38. Rhee K, Kim YY, Nam DH, Jung HR. Comparison of visual field defects between primary open-angle glaucoma and chronic primary angle-closure glaucoma in the early or moderate stage of the disease. Korean J Ophthalmol 2001; 15:27-31.
PMid:11530818
 
39. Shapiro A, Zauberman H. Diurnal changes of the intraocular pressure of patients with angle-closure glaucoma. Br J Ophthalmol 1979; 63:225-7.
http://dx.doi.org/10.1136/bjo.63.4.225
 
40. Asrani S, Zeimer R, Wilensky J, et al. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9:134-42.
http://dx.doi.org/10.1097/00061198-200004000-00002
 
41. Statistics Singapore. Population in brief: 2009. In: Department of Statistics Singapore [online]. Available at: www.nptd.gov.sg/.../Population%20in%20Brief%202009.pdf. Accessed January 28, 2013.

Comparison of risk of malignancy indices in evaluating ovarian masses in a Southeast Asian population

Share this Article

Singapore Med J 2013; 54(3): 136-139; http://dx.doi.org/doi:10.11622/smedj.2013046
Comparison of risk of malignancy indices in evaluating ovarian masses in a Southeast Asian population

Ong C, Biswas A, Choolani M, Low JJ
Correspondence: A/Prof Jeffrey Low, jeffrey_low@nuhs.edu.sg

ABSTRACT
Introduction The risk of malignancy index (RMI) is a scoring system used to triage benign from malignant ovarian masses. We compared the specificity and sensitivity of the four indices (RMI 1, RMI 2, RMI 3 and RMI 4) to discriminate a benign ovarian mass from a malignant one in a Southeast Asian population.
Methods This was a five-year retrospective study of women who were admitted for surgery due to ovarian masses. RMI scores were calculated based on standardised preoperative cancer antigen (CA)-125 levels, ultrasonography findings, menopausal status and tumour size based on ultrasonography. Postoperative histopathologic diagnosis was regarded as the definite outcome. Data were analysed using the Statistical Package for the Social Sciences, and Mann-Whitney U test was used to compare the individual RMI scores between the benign and malignant cases.
Results Out of the 480 patients reviewed, 228 women aged 10–65 years were included in the study. Of these, 17 (7.5%) had malignant disease and 211 (92.5%) had benign pathology. There was no statistical difference in the RMI 1, 2, 3 and 4 scores between the benign and malignant cases. Individual variables that were analysed showed significant differences in median CA-125 level and tumour size (p = 0.044 and p < 0.0005, respectively) between the benign and malignant cases.
Conclusion Our study shows that RMI is not a valuable triage tool for our Southeast Asian population. Further prospective validation, with regard to standardising results in different patient populations and centres, is required.

Keywords: CA125, ovarian cancer, risk of malignancy index, ultrasonography
Singapore Med J 2013; 54(3): 136-139; doi:10.11622/smedj.2013046

REFERENCES

1. Trends in cancer incidence in Singapore 1968-2007. Singapore Cancer Registry Report Number 7. Singapore: National Registry of Diseases Office, 2010.
 
2. Singapore Cancer Registry interim report. Trends in cancer incidence in Singapore, 2004-2008. Singapore: National Registry of Diseases Office, 2010.
 
3. Junor EJ, Hole DJ, McNulty L, Mason M, Young J. Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients. Br J Obstet Gynaecol 1999; 106:1130-6.
 
4. Jacobs I, Oram D, Fairbanks J, et al. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol 1990; 97:922-9.
 
5. Tingulstad S, Hagen B, Skjeldestad FE, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre-operative diagnosis of pelvic masses. Br J Obstet Gynaecol 1996; 103:826-31.
 
6. Tingulstad S, Hagen B, Skjeldestad FE, et al. The risk-of-malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol 1999; 93:448-52.
PMid:10074998
 
7. Morgante G, la Marca A, Ditto A, De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999; 106:524-7.
 
8. Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. Eur J Obstet Gynecol Reprod Biol 2009; 144:163-7.
 
9. Manjunath AP, Pratapkumar, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecol Oncol 2001; 81:225-9.
 
10. Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol 1993; 100:927-31.
 
11. Molina R, Escudero JM, Augé JM, et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patient s with g ynaecological diseases. Tumour Biol 2011; 32:1087-95.
 
12. Moore RG, Jabre-Raughley M, Brown AK, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 2010; 203:228.e1-6.
 
13. Andersen MR, Goff BA, Lowe KA, et al. Use of a Symptom Index, CA125, and HE4 to predict ovarian cancer. Gynecol Oncol 2010; 116:378-83.

The anatomical safe zone for medial opening oblique wedge high tibial osteotomy

Share this Article

Singapore Med J 2013; 54(2): 102-104; http://dx.doi.org/10.11622/smedj.2013033
The anatomical safe zone for medial opening oblique wedge high tibial osteotomy

Vanadurongwan B, Siripisitsak T, Sudjai N, Harnroongroj T
Correspondence: Prof Thossart Harnroongroj, tmthr@mahidol.ac.th

ABSTRACT
Introduction The end of medial opening oblique wedge high tibial osteotomy (HTO) points into a narrow area between the articular cartilage of the posterolateral proximal tibia and proximal tibiofibular joint (PTFJ) at the tibial site, which is an anatomical safe zone (ASZ) for osteotomy. We studied the ASZ and its relation to the fibular tip, including the level of posterior cruciate ligament (PCL) insertion, to avoid penetration into the knee and PTFJ, and PCL injury by osteotomy.
Methods Ten pairs of embalmed cadaveric legs were disarticulated at the knee joint and then examined. Soft tissues at the proximal tibia were removed. The posterior capsule of the PTFJ was incised to identify the articular cartilage of the PTFJ at the tibial site. The height of the fibular tip and the thickness of the ASZ were measured and calculated to determine the relationship between the ASZ and fibular tip. The level of PCL insertion was measured from the posterior articular surface of the proximal tibia to the distal attachment of the PCL.
Results The average height of the fibular tip and the thickness of the ASZ were 5.43 ± 1.53 mm and 4.12 ± 1.60 mm, respectively. On average, the fibular tip was 1.31 ± 1.28 mm higher than the ASZ, and the level of PCL insertion was 10.10 ± 1.88 mm.
Conclusion To ensure safety during medial opening oblique wedge HTO, the end of osteotomy should point accurately into the ASZ at a level just below the fibular tip as reference. Proximal osteotomy thickness should not be less than 10 mm at the level of PCL insertion.

Keywords: anatomical safe zone, fibular tip, medial opening oblique wedge high tibial osteotomy, posterior cruciate insertion
Singapore Med J 2013; 54(2): 102–104; http://dx.doi.org/10.11622/smedj.2013033

REFERENCES

1. Harnroongroj T, Vanadurongwan V. The stable upper tibial osteotomy for the treatment of osteoarthritis knee: lateral closing step wedge osteotomy (Part I). Siriraj Med J 1993; 45:829-36
 
2. Harnroongroj T, Vanadurongwan V. The stable upper tibial osteotomy for the treatment of osteoarthritic knee: Medial opening step wedge technique (Part II). Siriraj Med J 1994; 46:28-33.
 
3. Harnroongroj T, Vanadurongwan V. The stable upper tibial osteotomy for treatment of osteoarthritic knee (Part III): the simplified medial opening step wedge technique. Siriraj Med J 1994; 46:120-5.
 
4. Schallberger A, Jacobi M, Wahl P, Maestretti G, Jakob RP. High tibial valgus osteotomy in unicompartmental medial osteoarthritis of the knee: a retrospective follow-up study over 13-21 years. Knee Surg Sports Traumatol Arthrosc 2011; 19:122-7.
http://dx.doi.org/10.1007/s00167-010-1256-4
 
5. Bozkurt M, Yilmaz E, Atlihan D, et al. The proximal tibiofibular joint: an anatomic study. Clin Orthop Relat Res 2003; 406:136-40.
http://dx.doi.org/10.1097/00003086-200301000-00022
 
6. Eichenblat M, Nathan H. The proximal tibiofibular joint. An anatomical study with clinical and pathological considerations. Int Orthop 1983; 7:31-9.
 
7. Song EK, Seon JK, Park SJ, Jeong MS. The complications of high tibial osteotomy: closing-versus opening wedge method. J Bone Joint Surg Br 2010; 92:1245-52.
http://dx.doi.org/10.1302/0301-620X.92B9.23660
 
8. Spahn G. Complications in high tibial (medial opening wedge) osteotomy. Arch Orthop Trauma Surg 2004; 124:649-53.
http://dx.doi.org/10.1007/s00402-003-0588-7
 
9. Esenkaya I, Elmali N, Kaygusuz MA, Misirlio?lu M, Atasever A. [Assessment of the vulnerability of the proximal tibiofibular joint to injury during osteotomies]. Acta Orthop Traumatol Turc 2006; 40:396-402. Turkish.
 
10. Coventry MB. Osteotomy of the upper portion of the tibia for degenerative arthritis of the knee. J Bone Joint Surg Am 1965; 47:984-90.
 
11. Coventry MB. Upper tibial osteotomy for osteoarthritis. J Bone Joint Surg Am 1985; 67:1136-40.
 
12. Franco V, Cerullo G, Cipolla M, et al. Open wedge high tibial osteotomy. Tech Knee Surg 2002 2002; 1:43-53.
http://dx.doi.org/10.1097/00132588-200209000-00006
 
13. Ogden JA. The anatomy and function of the proximal tibiofibular joint. Clin Orthop Relat Res 1974; 101:186-91.

Evaluation of the National Cervical Cancer Screening Programme in Singapore

Share this Article

Singapore Med J 2013; 54(2): 96-101; http://dx.doi.org/10.11622/smedj.2013032
Evaluation of the National Cervical Cancer Screening Programme in Singapore

Jin AZ, Louange EC, Chow KY, Fock C
Correspondence: Dr Jin Ai Zhen, Jin_ Ai_ Zhen@hpb.gov.sg

ABSTRACT
Introduction
A retrospective observational study was performed to evaluate the effectiveness of CervicalScreen Singapore (CSS), a National Cervical Cancer Screening Programmme.
Methods National trends on incidence, mortality of cervical cancer and carcinoma in situof the cervix before and after the launch of CSS were examined. Linear regression was used to calculate the average annual percentage change in age-standardised incidence and mortality rates. We also examined the operational measures of CSS, such as the women who joined the CSS programme and the diagnostic accuracy of Pap smears. The study was confined to women who consented to join CSS at government-funded polyclinics.
Results Nationally, there was a greater decline in the age-standardised incidence and mortality rates in the period 2004–2008 as compared to the period 1987–2003. Under CSS, a total of 99,759 Pap smears were performed on 81,087 women in the period 2004–2008. However, the number of first screens decreased from 18,434 in 2004 to 11,624 in 2008. Among women aged 25–69 years who had their first Pap smear screening and who were recommended for routine rescreen in three years, 10% had a subsequent rescreen within three years. Overall, the CSS programme was able to detect 0.37 invasive cancers per 1,000 screens in women aged 25–69 years.
Conclusion The CSS programme has contributed to a decline in the mortality and incidence of cervical cancer in Singapore. However, the challenges of increasing the screening uptake among eligible women need to be addressed.

Keywords: cervical cancer screening, effectiveness, evaluation
Singapore Med J 2013; 54(2): 96–101; http://dx.doi.org/10.11622/smedj.2013032

REFERENCES

1. The Globocan Project 2008 [online]. Available at: globocan.iarc.fr/. Accessed August 22, 2012.
 
2. Ahmad OB, Boschi-Pinto C, Lopez A, et al. Age standardization of rates: a new WHO standard [online]. Available at: www.who.int/healthinfo/paper31.pdf. Accessed August 22, 2012.
 
3. Läärä E, Day NE, Hakama M. Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programme. Lancet 1987; 1:1247-9.
http://dx.doi.org/10.1016/S0140-6736(87)92695-X
 
4. Canfell K, Sitas F, Beral V. Cervical cancer in Australia and the United Kingdom: comparison of screening policy and uptake, and cancer incidence and mortality. Med J Aust 2006; 185:482-6.
 
5. International Agency for Research on Cancer. IARC Handbooks of Cancer Prevention: Cervix Cancer Screening. Lyon: IARC Press, 2005.
 
6. Quinn M, Babb P, Jones J, Allen E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ 1999; 318:904-8.
http://dx.doi.org/10.1136/bmj.318.7188.904
 
7. Ministry of Health, Singapore. National Health Survey 1998.
 
8. Ministry of Health, Singapore. National Health Surveillance Survey 2007.
 
9. Draeby-Kristiansen J, Garsaae M, Bruun M, Hansen K. Ten years after cryosurgical treatment of cervical intraepithelial neoplasia. Am J Obstet Gynecol 1991; 165:43-5.
 
10. Andersen ES, Husth M. Cryosurgery for cervical intraepithelial neoplasia: 10-year follow-up. Gynecol Oncol 1992; 45:240-2.
http://dx.doi.org/10.1016/0090-8258(92)90297-V
 
11. Ministry of Health. Communicable Diseases Surveillance in Singapore 2010.
 
12. Ministry of Health, Singapore. National Health Survey 2010.
 
13. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340:1144-53.
http://dx.doi.org/10.1056/NEJM199904153401502
 
14. Wong LP, Wong YL, Low WY, Khoo EM, Shuib R. Knowledge and awareness of cervical cancer and screening among Malaysian women who have never had a Pap smear: a qualitative study. Singapore Med J 2009; 50:49-53.
 
15. Weller DP, Campbell C. Uptake in cancer screening programmes: a priority in cancer control. Br J Cancer 2009; 101:S55-9.
http://dx.doi.org/10.1038/sj.bjc.6605391
 
16. Fang CY, Ma GX, Tan Y, Chi N. A multifaceted intervention to increase cervical cancer screening among underserved Korean women. Cancer Epidemiol Biomarkers Prev 2007; 16:1298-302.
http://dx.doi.org/10.1158/1055-9965.EPI-07-0091
 
17. Meissner HI, Smith RA, Rimer BK, et al. Promoting cancer screening: learning from experience. Cancer 2004; 101(5 Suppl):1107-17.
http://dx.doi.org/10.1002/cncr.20507
 
18. Twinn SF, Holroyd E, Fabrizio C, et al. Increasing knowledge about and uptake of cervical cancer screening in Hong Kong Chinese women over 40 years. Hong Kong Med J 2007; 13:16-20.
 
19. Giordano L, Webster P, Anthony C, et al. Improving the quality of communication in organized cervical cancer screening programmes. Patient Educ Couns 2008; 72:130-6.
http://dx.doi.org/10.1016/j.pec.2008.02.010
 
20. Rahman S, Price JH, Dignan M, et al. Access to mammography facilities and detection of breast cancer by screening mammography: a GIS approach. Int J Canc Prev 2009; 2:403-13.
 
21. Goldhaber-Fiebert JD, Denny LE, De Souza M, et al. The costs of reducing loss to follow-up in South African cervical cancer screening. Cost Eff Resour Alloc 2005; 3:11.
http://dx.doi.org/10.1186/1478-7547-3-11
 
22. Simoes EJ, Newschaffer CJ, Hagdrup N, et al. Predictors of compliance with recommended cervical cancer screening schedule: a population-based study. J Community Health 1999; 24:115-30.
http://dx.doi.org/10.1023/A:1018754307718
 
23. Fernández-Esquer ME, Espinoza P, Ramirez AG, McAlister AL. Repeated Pap smear screening among Mexican-American women. Health Educ Res 2003; 18:477-87.
http://dx.doi.org/10.1093/her/cyf037
 
24. Goins KV, Zapka JG, Geiger AM, et al. Implementation of systems strategies for breast and cervical cancer screening services in health maintenance organizations. Am J Manag Care 2003; 9:745-55.
 
25. Karani A, De Vuyst H, Luchters S, et al. The Pap smear for detection of bacterial vaginosis. Int J Gynaecol Obstet 2007; 98:20-3.
http://dx.doi.org/10.1016/j.ijgo.2007.03.010
 
26 .Specificity, sensitivity and cost. Nat Rev Cancer 2007; 7:893. doi: 10.1038/nrc2287.
http://dx.doi.org/10.1038/nrc2287
 
27. Anttila A, Ronco G, Clifford G,et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004 31; 91:935-41.
 
28. Davidson M, Bulkow LR, Lanier AP, et al. Incidence of invasive cervical cancer preceded by negative screening in high-risk Alaska Native women. Int J Epidemiol 1994; 23:238-45.
http://dx.doi.org/10.1093/ije/23.2.238

Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia

Share this Article

Singapore Med J 2013; 54(2): 90-95; http://dx.doi.org/10.11622/smedj.2013031
Hypolipidaemic and anti-inflammatory effects of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia

Padhy BM, Yadav R, Gupta YK
Correspondence: Dr Biswa Mohan Padhy, drbisu7@gmail.com

ABSTRACT
Introduction
We aimed to assess the efficacy of fixed dose combination of atorvastatin plus ezetimibe in Indian patients with dyslipidaemia.
Methods A double-blind study was conducted to assess the effect of fixed dose combination of ezetimibe 10 mg plus atorvastatin 10 mg on lipid profile, oxidised low-density lipoprotein (ox-LDL), high-sensitivity C-reactive protein (hsCRP) and soluble intercellular cell adhesion molecule (sICAM) in dyslipidaemic patients with or at high risk of coronary artery disease, and compare it with atorvastatin 10 mg monotherapy. 30 patients were randomised to receive ezetimibe plus atorvastatin or atorvastatin once daily for four weeks.
Results Of the 30 patients, 10 men and 5 women (mean age 54.3 ± 1.6 years) received ezetimibe plus atorvastatin, while 13 men and 2 women (mean age 53.7 ± 2.8 years) received only atorvastatin. The combination treatment significantly reduced total cholesterol (percentage treatment difference −14.4 ± 6.5, 95% confidence interval [CI] −1.0 to −27.7; p = 0.041) and LDL cholesterol (LDL-C; percentage treatment difference −19.9 ± 6.1, 95% CI −7.4 to −32.4; p = 0.003) compared to atorvastatin monotherapy. 13 patients on combination treament achieved the National Cholesterol Education Program target for LDL-C as compared to 9 patients on atorvastatin monotherapy (p = 0.032). Significant reductions in very low-density lipoprotein cholesterol, triglyceride, ox-LDL and sICAM were observed with combination treatment compared to atorvastatin monotherapy. However, no significant change was seen in high-density lipoprotein cholesterol or hsCRP levels between the two groups.
Conclusion Combination treatment with atorvastatin and ezetimibe had relatively better lipid-lowering and anti-inflammatory efficacy than atorvastatin monotherapy.

Keywords: atorvastatin, ezetimibe, high sensitivity C-reactive protein, intercellular cell adhesion molecule
Singapore Med J 2013; 54(2): 90–95; http://dx.doi.org/10.11622/smedj.2013031

REFERENCES

1. Sharma M, Ganguly NK. Premature coronary artery disease in Indians and its associated risk factors. Vasc Health Risk Manag 2005; 1:217-25.
 
2. Goyal A, Yusuf S. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res 2006; 124:235-44.
 
3. Gupta R, Gupta VP, Sarna M, et al. Prevalence of coronary heart disease and risk factors in an urban Indian population: Jaipur Heart Watch-2. Indian Heart J 2002; 54:59-66.
 
4. Srinath Reddy K, Shah B, Varghese C, Ramadoss A. Responding to the threat of chronic diseases in India. Lancet 2005; 366:1744-9.
http://dx.doi.org/10.1016/S0140-6736(05)67343-6
 
5. Nixon JV. Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter? Vasc Health Risk Manag 2006; 2:441-6.
http://dx.doi.org/10.2147/vhrm.2006.2.4.441
 
6. Rutishauser J. The role of statins in clinical medicine-LDL—cholesterol lowering and beyond. Swiss Med Wkly 2006; 136:41-9.
 
7. Davignon J, Leiter LA. Ongoing clinical trials of the pleiotropic effects of statins. Vasc Health Risk Manag 2005; 1:29-40.
http://dx.doi.org/10.2147/vhrm.1.1.29.58937
 
8. Liao JK. Isoprenoids as mediators of the biological effects of statins. J Clin Invest 2002; 110:285-8.
 
9. Miida T, Hirayama S, Nakamura Y. Cholesterol-independent effects of statins and new therapeutic targets: ischemic stroke and dementia. J Atheroscler Thromb 2004; 11:253-64.
http://dx.doi.org/10.5551/jat.11.253
 
10 .Hamilton-Craig I, Kostner K, Colquhoun D, Woodhouse S. Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag 2010; 6:1023-37.
http://dx.doi.org/10.2147/VHRM.S13496
 
11. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-32.
http://dx.doi.org/10.1016/j.jacc.2004.07.001
 
12. Backes JM, Gibson CA, Howard PA. Optimal lipid modification: the rationale for combination therapy. Vasc Health Risk Manag 2005; 1:317-31.
http://dx.doi.org/10.2147/vhrm.2005.1.4.317
 
13. Neal RC, Jones PH. Complementary therapy to target LDL cholesterol: the role of the ezetimibe/simvastatin combination. Vasc Health Risk Manag 2006; 2:31-8.
http://dx.doi.org/10.2147/vhrm.2006.2.1.31
 
14. Al Badarin FJ, Kullo IJ, Kopecky SL, Thomas RJ. Impact of ezetimibe on atherosclerosis: is the jury still out? Mayo Clin Proc 2009; 84:353-61.
 
15. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358:1431-43.
http://dx.doi.org/10.1056/NEJMoa0800742
 
16. Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80:587-95.
http://dx.doi.org/10.4065/80.5.587
 
17. Landmesser U, Bahlmann F, Mueller M, et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111:2356-63.
http://dx.doi.org/10.1161/01.CIR.0000164260.82417.3F
 
18. Jayaram S, Jain SD, Bhatia G, et al. Assessment of the efficacy, safety and tolerability of ezetimibe 10mg in adult patients with primary hypercholesterolemia: The first Indian Study. Indian Pract 2004; 57:73-9.
 
19. Athyros VG, Tziomalos K, Kakafika AI, et al. Effectiveness of ezetimibe alone or in combination with twice a week atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol 2008; 101:483-5.
http://dx.doi.org/10.1016/j.amjcard.2007.09.096
 
20. nFarcas A, Bojita M. Adverse drug reactions in clinical practice: a causality assessment of a case of drug-induced pancreatitis. J Gastrointestin Liver Dis 2009; 18:353-8.
 
21. Mohan V, Deepa R, Rani SS, Premalatha G, Chennai Urban Population Study (CUPS No.5). Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai Urban Population Study (CUPS No. 5). J Am Coll Cardiol 2001; 38:682-7.
http://dx.doi.org/10.1016/S0735-1097(01)01415-2
 
22. Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am Heart J 2005; 149:464-73.
http://dx.doi.org/10.1016/j.ahj.2004.11.023
 
23. Piorkowski M, Fischer S, Stellbaum C, et al. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets? J Am Coll Cardiol 2007; 49:1035-42.
http://dx.doi.org/10.1016/j.jacc.2006.10.064
 
24. Conard S, Bays H, Leiter LA, et al. Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patients at high risk for coronary heart disease with diabetes mellitus, metabolic syndrome or neither. Diabetes Obes Metab 2010; 12:210-8.
http://dx.doi.org/10.1111/j.1463-1326.2009.01152.x
 
25. Zieve F, Wenger NK, Ben-Yehuda O, et al. Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in Patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study). Am J Cardiol 2010; 105:656-63.
http://dx.doi.org/10.1016/j.amjcard.2009.10.029
 
26. Spratt KA. Reducing the risk of coronary heart disease via lipid reduction. J Am Osteopath Assoc 2004; 104:S9-13.
 
27. Grigore L, Norata GD, Catapano AL. Combination therapy in cholesterol reduction: focus on ezetimibe and statins. Vasc Health Risk Manag 2008; 4:267-78.
 
28. Mitra S, Deshmukh A, Sachdeva R, Lu J, Mehta JL. Oxidized low-density lipoprotein and atherosclerosis implications in antioxidant therapy. Am J Med Sci 2011; 342:135-42.
http://dx.doi.org/10.1097/MAJ.0b013e318224a147
 
29. Nagy L, Tontonoz P, Alvarez JG, Chen H, Evans RM. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998; 93:229-40.
http://dx.doi.org/10.1016/S0092-8674(00)81574-3
 
30. Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb 2010; 17:37-44.
http://dx.doi.org/10.5551/jat.1651
 
31. Fonseca HA, Izar MC, Bianco HT, Fonseca FA. Ezetimibe, oxidized low density lipoprotein, Lp (a), and dyslipidemia. J Atheroscler Thromb 2010; 17:888.
http://dx.doi.org/10.5551/jat.5918
 
32. Constance C, Westphal S, Chung N, et al. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2007; 9:575-84.
http://dx.doi.org/10.1111/j.1463-1326.2007.00725.x
 
33. Ridker PM, Cannon CP, Morrow D, et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005; 352:20-8.
http://dx.doi.org/10.1056/NEJMoa042378
 
34. Balk EM, Lau J, Goudas LC, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med 2003; 139:670-82.
 
35. Gupta M, Szmitko PE, Tsigoulis M, et al. Effects of ezetimibe add-on to statin therapy on adipokine production in patients with metabolic syndrome and stable vascular disease. J Cardiovasc Pharmacol 2010; 56:241-5.
http://dx.doi.org/10.1097/FJC.0b013e3181e7fd74
 
36. Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107:2409-15.
http://dx.doi.org/10.1161/01.CIR.0000068312.21969.C8
PMid:12719279
 
37. Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein: a meta-analysis. J Am Coll Cardiol 2007; 49:2003-9.
http://dx.doi.org/10.1016/j.jacc.2007.01.083
 
38. Blankenberg S, Rupprecht HJ, Bickel C, et al. Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation. 2001; 104:1336-42.
http://dx.doi.org/10.1161/hc3701.095949
 
39. Wijnstok NJ, Twisk JW, Young IS, et al. Inflammation markers are associated with cardiovascular diseases risk in adolescents: the Young Hearts project 2000. J Adolesc Health 2010; 47:346-51.
http://dx.doi.org/10.1016/j.jadohealth.2010.04.008
 
40. Rosenson RS, Wolff D, Tangney CC. Statins reduce oxidized low-density lipoprotein levels, but do not alter soluble intercellular cell-adhesion molecule-1 and vascular cell-adhesion molecule-1 levels in subjects with hypercholesterolaemia. Clin Sci (Lond) 2004; 106:215-7.
http://dx.doi.org/10.1042/CS20030291
 
41. Davidson MH, Maccubbin D, Stepanavage M, Strony J, Musliner T. Striated muscle safety of ezetimibe/simvastatin (Vytorin). Am J Cardiol 2006; 97:223-8.
http://dx.doi.org/10.1016/j.amjcard.2005.08.038
 
42. Florentin M, Liberopoulos EN, Elisaf MS. Ezetimibe-associated adverse effects: what the clinician needs to know. Int J Clin Pract 2008; 62:88-96.
http://dx.doi.org/10.1111/j.1742-1241.2007.01592.x
 
43. Foody JM, Brown WV, Zieve F, et al. Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥ 65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study). Am J Cardiol 2010; 106:1255-63.
http://dx.doi.org/10.1016/j.amjcard.2010.06.051
 
44. Denke M, Pearson T, McBride P, et al. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab Vasc Dis Res 2006; 3:93-102.
http://dx.doi.org/10.3132/dvdr.2006.020
 
45. Pearson TA, Denke MA, McBride PE, et al. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the Ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 2006; 81:1177-85.
http://dx.doi.org/10.4065/81.9.1177

Raised troponin I in Chinese patients with acute pulmonary embolism suggests complicated clinical course and may predict intensive care unit admission

Share this Article

Singapore Med J 2013; 54(2): 86-89; http://dx.doi.org/10.11622/smedj.2013030
Raised troponin I in Chinese patients with acute pulmonary embolism suggests complicated clinical course and may predict intensive care unit admission

Ng PL, Kwok CH, Tsui SH, Tong HK
Correspondence: Dr Pui-Lok Ng, lucypl@yahoo.com

ABSTRACT
Introduction Acute pulmonary embolism (PE) is an uncommon but potentially fatal disease. Acute right ventricular failure, which can be demonstrated by echocardiography, is known to be an adverse prognostic factor in patients with acute PE. However, this diagnostic test is not always available in emergency departments and it is also an operator-dependent investigation. This study aimed to investigate whether cardiac troponin I (cTnI) levels could predict clinical outcomes in Chinese patients with PE.
Methods This was a retrospective cohort study performed in a tertiary regional hospital in Hong Kong. For this study, 100 patients who were diagnosed with acute PE between January 1, 2002 and December 31, 2009 were recruited. Information, including demographic data, presenting symptoms and vital signs at presentation, predisposing factors for PE, results of diagnostic procedures and clinical outcomes, was collected from the medical records of these patients.
Results 71% of recruited patients had elevated cTnI levels. High cTnI levels were associated with haemodynamic instability (odds ratio [OR] 5.30, 95% confidence interval [CI] 1.32–27.71; p = 0.019) and complicated clinical course (OR 6.34, 95% CI 1.76–22.9; p = 0.002).
Conclusion Elevated cTnI level was associated with a complicated clinical course in patients with acute PE. We suggest that measurements of cTnI levels be used for the early risk stratification of patients with PE in the emergency departments of hospitals.

Keywords: cTnI, Chinese, PE, pulmonary embolism, troponin I
Singapore Med J 2013; 54(2): 86–89; http://dx.doi.org/10.11622/smedj.2013030

REFERENCES

1. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet 1999; 353:1386-9.
http://dx.doi.org/10.1016/S0140-6736(98)07534-5
 
2. Kasper W, Konstantinides S, Geibel A, et al. Prognostic significance of right ventricular afterload stress detected by echocardiography in patients with clinically suspected pulmonary embolism. Heart 1997; 77:346-9.
 
3. Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol 2000; 36:959-69.
http://dx.doi.org/10.1016/S0735-1097(00)00804-4
 
4. Kucher N, Wallmann D, Carone A, et al. Incremental prognostic value of troponin I and echocardiography in patients with acute pulmonary embolism. Eur Heart J 2003; 24:1651-6.
http://dx.doi.org/10.1016/S0195-668X(03)00394-4
 
5. Mehta NJ, Jani K, Khan IA. Clinical usefulness and prognostic value of elevated cardiac troponin I levels in acute pulmonary embolism. Am Heart J 2003; 145:821-5.
http://dx.doi.org/10.1016/S0002-8703(02)94704-6
 
6. Konstantinides S, Geibel A, Olschewski M, et al. Importance of cardiac troponins I and T in risk stratification of patients with acute pulmonary embolism. Circulation 2002; 106:1263-8.
http://dx.doi.org/10.1161/01.CIR.0000028422.51668.A2
 
7. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158:585-93.
http://dx.doi.org/10.1001/archinte.158.6.585
 
8. Liu HS, Kho BC, Chan JC, et al. Venous thromboembolism in the Chinese population--experience in a regional hospital in Hong Kong. Hong Kong Med J 2002; 8:400-5.
 
9. Chan LC, Bourke C, Lam CK, et al. Lack of activated protein C resistance in healthy Hong Kong Chinese blood donors-correlation with absence of Arg506-Gln mutation of factor V gene. Thromb Haemost 1996; 75:522-3.
PMid:8701422
 
10. Aksay E, Yanturali S, Kiyan S. Can elevated troponin I levels predict complicated clinical course and inhospital mortality in patients with acute pulmonary embolism? Am J Emerg Med 2007; 25:138-43.
http://dx.doi.org/10.1016/j.ajem.2006.06.005
 
11. Kasper W, Konstantinides S, Geibel A, et al. Management strategies and determinants of outcome in acute major pulmonary embolism: results of a multicenter registry. J Am Coll Cardiol 1997; 30:1165-71.
http://dx.doi.org/10.1016/S0735-1097(97)00319-7
 
12. Torbicki A, Perrier A, Konstantinides S, et al. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J 2008; 29:2276-315.
http://dx.doi.org/10.1093/eurheartj/ehn310
 
13. Goldhaber SZ. Pulmonary embolism. Lancet 2004; 363:1295-305.
http://dx.doi.org/10.1016/S0140-6736(04)16004-2
 
14. Meyer T, Binder L, Hruska N, Luthe H, Buchwald AB. Cardiac troponin I elevation in acute pulmonary embolism is associated with right ventricular dysfunction. J Am Coll Cardiol 2000; 36:1632-6.
http://dx.doi.org/10.1016/S0735-1097(00)00905-0
 
15. Giannitsis E, Müller-Bardorff M, Kurowski V, et al. Independent prognostic value of cardiac troponin T in patients with confirmed pulmonary embolism. Circulation 2000; 102:211-7.
http://dx.doi.org/10.1161/01.CIR.102.2.211
 
16. Becattini C, Vedovati MC, Agnelli G. Prognostic value of troponins in acute pulmonary embolism: a meta-analysis. Circulation 2007; 116:427-33.
http://dx.doi.org/10.1161/CIRCULATIONAHA.106.680421
 
17. Punukollu G, Khan IA, Gowda RM, et al. Cardiac troponin I release in acute pulmonary embolism in relation to the duration of symptoms. Int J Cardiol 2005; 99:207-11.
http://dx.doi.org/10.1016/j.ijcard.2004.01.012
 
18. Pruszczyk P, Bochowicz A, Torbicki A, et al. Cardiac troponin T monitoring identifies high-risk group of normotensive patients with acute pulmonary embolism. Chest 2003; 123:1947-52
http://dx.doi.org/10.1378/chest.123.6.1947
 
19. Müller-Bardorff M, Weidtmann B, Giannitsis E, Kurowski V, Katus HA. Release kinetics of cardiac troponin T in survivors of confirmed severe pulmonary embolism. Clin Chem 2002; 48:673-5.